OH-selected AGB and post-AGB stellar objects II.Blue versus red evolution off the AGB

Using objects found in a systematic survey of the galactic Plane in the 1612-MHz OH line, we discuss in detail two ``sequences'' of post-AGB evolution, a red and a blue. We argue that the red and the blue groups separate by initial mass at 4Msun, based on evolutionary-sequence turn-off colours, spectral energy distributions, outflow velocities and scaleheight. The higher-mass (blue) objects may have earlier AGB termination. The lower-mass (red) objects undergo very sudden reddening for IRAS colour R21\sim1.2; these sources must all undergo a very similar process at AGB termination. The transition colour corresponds to average initial masses of 1.7Msun. A combined IRAS-MSX colour proves a very sensitive tool to distinguish lower-mass, early post-AGB objects from sources still on the AGB and also to distinguish more evolved post-AGB objects from star-forming regions. The high-mass blue objects are the likely precursors of bipolar planetary nebulae, whereas the low-mass red objects will evolve into elliptical planetary nebulae.Comment: 12 pages, LaTex, 7 figures (1 colour), AJ (accepted

HST Snapshot Survey of Post-AGB Objects

The results from a Hubble Space Telescope (HST) snapshot survey of post-AGB objects are shown. The aim of the survey is to complement existing HST images of PPN and to connect various types of nebulosities with physical and chemical properties of their central stars. Nebulosities are detected in 15 of 33 sources. Images and photometric and geometric measurements are presented. For sources with nebulosities we see a morphological bifurcation into two groups, DUPLEX and SOLE, as previous studies have found. We find further support to the previous results suggesting that this dichotomy is caused by a difference in optical thickness of the dust shell. The remaining 18 sources are classified as stellar post-AGB objects, because our observations indicate a lack of nebulosity. We show that some stellar sources may in fact be DUPLEX or SOLE based on their infrared colors. The cause of the differences among the groups are investigated. We discuss some evidence suggesting that high progenitor-mass AGB stars tend to become DUPLEX post-AGB objects. Intermediate progenitor-mass AGB stars tend to be SOLE post-AGB objects. Most of the stellar sources probably have low mass progenitors and do not seem to develop nebulosities during the post-AGB phase and therefore do not become planetary nebulae.Comment: 21 pages, 11 figure

An evolutionary catalogue of Galactic post-AGB and related objects

With the ongoing AKARI infrared sky survey, of much greater sensitivity than IRAS, a wealth of post-AGB objects may be discovered. It is thus time to organize our present knowledge of known post-AGB stars in th galaxy with a view to using it to search for new post-AGB objects among AKARI sources. We searched the literature available on the NASA Astrophysics Data System up to 1 October 2006, and defined criteria for classifying sources into three categories: "very likely", "possible" and "disqualified" post-AGB objects. The category of "very likely" post-AGB objects is made up of several classes. We have created an evolutionary, on-line catalogue of Galactic post-AGB objects, to be referred to as "The Torun catalogue of Galactic post-AGB and related objects". The present version of the catalogue contains 326 "very likely", 107 "possible" and 64 "disqualified" objects. For the very likely post-AGB objects, the catalogue gives the available optical and infrared photometry, infrared spectroscopy and spectral types, and links to finding charts and bibliography.Comment: 9 pages, 6 figures, accepted for publication in A&

Bioengineering of Improved Biomaterials Coatings for Extracorporeal Circulation Requires Extended Observation of Blood-Biomaterial Interaction under Flow

Extended use of cardiopulmonary bypass (CPB) systems is often hampered by thrombus formation and infection. Part of these problems relates to imperfect hemocompatibility of the CPB circuitry. The engineering of biomaterial surfaces with genuine long-term hemocompatibility is essentially virgin territory in biomaterials science. For example, most experiments with the well-known Chandler loop model, for evaluation of blood-biomaterial interactions under flow, have been described for a maximum duration of 2 hours only. This study reports a systematic evaluation of two commercial CPB tubings, each with a hemocompatible coating, and one uncoated control. The experiments comprised (i) testing over 5 hours under flow, with human whole blood from 4 different donors; (ii) measurement of essential blood parameters of hemocompatibility; (iii) analysis of the luminal surfaces by scanning electron microscopy and thrombin generation time measurements. The dataset indicated differences in hemocompatibility of the tubings. Furthermore, it appeared that discrimination between biomaterial coatings can be made only after several hours of blood-biomaterial contact. Platelet counting, myeloperoxidase quantification, and scanning electron microscopy proved to be the most useful methods. These findings are believed to be relevant with respect to the bioengineering of extracorporeal devices that should function in contact with blood for extended time

Developing hierarchically porous MnO_<em>x</em>/NC hybrid nanorods for oxygen reduction and evolution catalysis

Electrochemical oxygen reduction and evolution reactions (ORR and OER) play a vital role in the field of energy conversion and storage. The problem is that both processes are sluggish, requiring precious-metal catalysts. Here, starting from abundant precursors and using a simple synthesis approach, we report the preparation of a good bifunctional oxygen electro-catalyst: a composite nanorod of manganese oxides and nitrogen-doped carbon. This material has hierarchical porosity, facilitating the mass transfer within the electrode. The nitrogen-doped carbon forms contiguous 3D network, connecting the isolated MnOx nanoparticles and ensuring superior electrical conductivity. Importantly, the MnOx particles contain manganese of mixed oxidation states; aligned with the nitrogen-doped carbon, this hybrid is among the best non-noble-metal ORR/OER catalysts in alkaline media, outperforming even Pt and RuO2 catalysts.Peer reviewed: YesNRC publication: Ye

Zr-89-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs

Background To better predict response to immune checkpoint therapy and toxicity in healthy tissues, insight in the in vivo behavior of immune checkpoint targeting monoclonal antibodies is essential. Therefore, we aimed to study in vivo pharmacokinetics and whole-body distribution of zirconium-89 (Zr-89) labeled programmed cell death protein-1 (PD-1) targeting pembrolizumab with positron-emission tomography (PET) in humanized mice. Methods Humanized (huNOG) and non-humanized NOG mice were xenografted with human A375M melanoma cells. PET imaging was performed on day 7 post(89)Zr-pembrolizumab (10 mu g, 2.5 MBq) administration, followed by ex vivo biodistribution studies. Other huNOG mice bearing A375M tumors received a co-injection of excess (90 mu g) unlabeled pembrolizumab or(89)Zr-IgG(4)control (10 mu g, 2.5 MBq). Tumor and spleen tissue were studied with autoradiography and immunohistochemically including PD-1. Results PET imaging and biodistribution studies showed high(89)Zr-pembrolizumab uptake in tissues containing human immune cells, including spleen, lymph nodes and bone marrow. Tumor uptake of(89)Zr-pembrolizumab was lower than uptake in lymphoid tissues, but higher than uptake in other organs. High uptake in lymphoid tissues could be reduced by excess unlabeled pembrolizumab. Tracer activity in blood pool was increased by addition of unlabeled pembrolizumab, but tumor uptake was not affected. Autoradiography supported PET findings and immunohistochemical staining on spleen and lymph node tissue showed PD-1 positive cells, whereas tumor tissue was PD-1 negative. Conclusion Zr-89-pembrolizumab whole-body biodistribution showed high PD-1-mediated uptake in lymphoid tissues, such as spleen, lymph nodes and bone marrow, and modest tumor uptake. Our data may enable evaluation of(89)Zr-pembrolizumab whole-body distribution in patients

Routine versus on demand removal of the syndesmotic screw; a protocol for an international randomised controlled trial (RODEO-trial)

Background: Syndesmotic injuries are common and their incidence is rising. In case of surgical fixation of the syndesmosis a metal syndesmotic screw is used most often. It is however unclear whether this screw needs to be removed routinely after the syndesmosis has healed. Traditionally the screw is removed after six to 12 weeks as it is thought to hamper ankle functional and to be a source of pain. Some studies however suggest this is only the case in a minority of patients. We therefore aim to investigate the effect of retaining the syndesmotic screw on functional outcome. Design: This is a pragmatic international multicentre randomised controlled trial in patients with an acute syndesmotic injury for which a metallic syndesmotic screw was placed. Patients will be randomised to either routine removal of the syndesmotic screw or removal on demand. Primary outcome is functional recovery at 12 months measured with the Olerud-Molander Score. Secondary outcomes are quality of life, pain and costs. In total 194 patients will be needed to demonstrate non-inferiority between the two interventions at 80% power and a significance level of 0.025 including 15% loss to follow-up. Discussion: If removal on demand of the syndesmotic screw is non-inferior to routine removal in terms of functional outcome, this will offer a strong argument to adopt this as standard practice of care. This means that patients will not have to undergo a secondary procedure, leading to less complications and subsequent lower costs.Peer reviewe